ClinicalTrials.gg
RecruitingNCT06374459Updated Oct 13, 2026

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

A Phase 1/2 interventional study of Zumsemetinib and Capecitabine in Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer, sponsored by Washington University School of Medicine. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Washington University School of Medicine · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 13, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies in Breast Neoplasms by Washington University School of Medicine — 18 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Washington University School of Medicine.

Planned enrollment
12th of 74
152 · median 55
Started
2025
with 4 others
Phase 1/2
2 of 80
1 open now
Primary completion
2032-05
later than 18 of 21 live
Registered
67th of 80
by date

Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, this one is the 12th largest by planned enrollment of the 74 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 18 of the 21 other live ones, and was the 67th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

18 of the 80 studies in Breast Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Breast Neoplasms by Washington University School of Medicine, or all of them as a file.
02

Study summary

This is a phase Ib/II study evaluating the safety and efficacy of zunsemetinib (ATI-450) with capecitabine in patients with hormone receptor-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC).

03

Conditions studied

  • Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer

Browse trials for

Keywords

  • Zunsemetinib
  • ATI-450
  • MK-2
  • Bone metastasis
  • Breast Cancer
  • HR-positive/HER2-negative
  • Capecitabine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for both Phase Ib and Phase II:

  • Hormone receptor-positive, -negative breast cancer.
  • Measurable or non-measurable but evaluable disease by v1.1.
  • Candidate for capecitabine treatment per physician decision. See below phase-specific eligibility criteria for further guidance.
  • No more than one prior chemotherapy for metastatic disease.
  • Patient must have received prior endocrine therapy with CDK4/6 inhibitor.
  • If patient is on denosumab or zoledronic acid prior to enrollment, patient must have been on the regimen for at least 6 months prior to study. However, a of 3 weeks is required prior to C1D1.
  • At least 18 years of age.
  • performance status 0, 1, or 2
  • of at least 12 weeks.
  • Adequate bone marrow and organ function as defined below:

    • Leukocytes ≥ 3 K/cumm
    • (ANC) ≥ 1.5 K/cumm
    • ≥ 100 K/cumm
    • Total ≤ 1.5 x IULN (or total bilirubin ≤ 3 mg/dL if patient has known Gilbert Syndrome)
    • (SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • > 60 mL/min by Cockcroft-Gault
    • Calcium within normal limits
  • Women of and men who are heterosexually active must agree to use adequate as specified in the protocol. Contraception should continue for 6 months (for women) or 3 months (for men) after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written document.
  • Patients must have sample available from prior metastatic biopsy. If no tissue is available, patient may still be able to enroll with PI approval.

Inclusion Criteria for both Phase Ib:

  • Presence of bone metastasis is not required.
  • Candidate for, or currently on stable doses of capecitabine, defined as capecitabine: 1000 mg/m\^2 BID, 14 days on and 7 days off. A stable dose of capecitabine is defined as no more than grade 1 AEs related to capecitabine on the 1000 mg/m\^2 BID, 14 days on and 7 days off dose for at least 1 cycle. Capecitabine is not counted as a prior chemotherapy regimen in these patients.

Inclusion Criteria for Phase II:

  • Progressive bone metastasis per the most recent tumor imaging studies by RECIST 1.1 or clinical progression (such as worsening bone pain, elevation of tumor marker) per treating physician.

Exclusion Criteria for both Phase Ib and Phase II:

  • Patients may not have received the following or SOC therapies within the below specified time frames prior to C1D1:

    • Radiation therapy within 1 week
    • Systemic chemotherapy, including antibody drug conjugates with chemotherapy payload, within 3 weeks.
    • Immunotherapy within 3 weeks
    • Oral chemotherapy or molecularly targeted therapy within 5 half-lives of the agent.
    • Endocrine therapies do not have a required washout and may be continued until C1D1.
    • Strong and moderate and CYP2C8 inhibitors (including grapefruit), strong and moderate CYP3A and CYP2C8 inducers, and drugs with prolonging potential within 5 half-lives of the agent.
  • Untreated . Patients with treated brain metastases are eligible if they show no evidence of progression and are off .
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to zunsemetinib or other agents used in the study.
  • History of acute, untreated skeletal related events (SRE) or active untreated SRE or a change or an anticipated change in the SOC anti-resorptive agents after entering the study.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of C1D1.
  • Patients with are eligible unless their are \< 350 cells/mcL or they have a history of AIDS-defining opportunistic infection within the 12 months prior to Cycle 1 Day 1. Concurrent treatment with effective ART according to DHHS treatment guidelines is recommended.
  • Screening resting QTcF above 470 msec.

Exclusion Criteria for Phase Ib:

  • Capecitabine within 2 weeks prior to C1D1. Patients may be currently taking capecitabine, but must not have dosed within 2 weeks prior to C1D1 for study correlative purposes.

Exclusion Criteria for Phase II:

  • Prior capecitabine in the metastatic setting.
  • History of other , unless all treatment was completed and patient had no evidence of disease within 2 years of C1D1.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
152 participants (estimated)

Study arms

  • Experimental
    Phase Ib: Zunsemetinib + Capecitabine

    Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose along with capecitabine (1000 mg/m\^2 PO BID on Days 1-14 an every 21-day cycle). For patients enrolled in phase Ib, capecitabine is dosed on days 2-15 during cycles 1-2. Dose escalation of zunsemetinib will utilize a 3+3 design. A maximum of 3 dose levels of zunsemetinib will be tested, and the two highest dose levels which did not lead to more than 1 of 6 patients with DLT in cycle 1 will be chosen as the RP2D-L1 and RP2D-L2 for Phase II. If only one dose level of zunsemetinib was found tolerable, then only one RP2D will be chosen for Phase II.

    Drug: Zumsemetinib · Drug: Capecitabine

  • Active comparator
    Phase II Arm 1: Standard of care anti-resorptive + Capecitabine

    Standard of care anti-resorptives will consist of bisphosphonate (zoledronic acid) is to be administered every 4-12 weeks, or denosumab is to be administered every 4-6 weeks, as per physician choice and institutional practice. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3.

    Drug: Capecitabine · Drug: Zoledronic acid · Drug: Denosumab

  • Experimental
    Phase II Arm 2: Zunsemetinib (RP2D-L1) + Capecitabine

    Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3.

    Drug: Zumsemetinib · Drug: Capecitabine

  • Experimental
    Phase II Arm 3: Zunsemetinib (RP2D-L2) + Capecitabine

    Patients will receive zunsemetinib by mouth (PO) twice per day (BID) at an assigned dose. In general, capecitabine will be taken twice daily at a dose of 1000 mg/m\^2 on Days 1 through 14 of every 21-day cycle. The first 4 patients enrolling to phase II will take capecitabine on a different schedule for PK purposes in Cycles 1 and 2 ONLY. Patients will take capecitabine at a dose of 1000mg/m\^2 on Days 2 through 15 of Cycles 1 and 2, and then on Days 1 through 14 starting with Cycle 3. If only one dose level of zunsemetinib plus capecitabine was found tolerable in phase Ib testing, the phase II trial will proceed with 2:1 two-arm randomization with Arm 2 of capecitabine plus zunsemetinib and Arm 1 of capecitabine plus standard of care anti-resorptive agent.

    Drug: Zumsemetinib · Drug: Capecitabine

Interventions

  • DrugZunsemetinibStudies of ZunsemetinibZunsemetinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients should take zunsemetinib at approximately the same times every day, with or without food with 8 oz of water.

    Also known as: ATI-450

  • Patients should take capecitabine at approximately the same times every day, within 30 minutes after a meal.

  • Standard of care. Will receive zoledronic acid or denosumab.

  • Standard of care. Will receive zoledronic acid or denosumab.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (Phase Ib only)

    Time frame: From start of treatment through 30 days after end of treatment (estimated to be 11 months)

  2. Recommended phase II dose of zunsemetinib (Phase Ib only)

    Time frame: Through end of 1st cycle (each cycle is 21 days)

  3. Number of participants with dose-limiting toxicities (Phase Ib only)

    Time frame: Through end of 1st cycle (each cycle is 21 days)

  4. Percent change in serum CTX (Phase II only)

    Time frame: Baseline and Day 1 of week 7

  5. Progression-free survival (PFS) (Phase II only)

    Time frame: From start of treatment through completion of follow-up (estimated to be 3 years and 10 months)

Secondary outcomes

  1. Treatment-induced changes in DEXA BMD (g/cm^2) at hip and spine (Phase Ib only)

    Time frame: Baseline, end of cycle 8 (each cycle is 21 days), and end of treatment (estimated to be 10 months)

  2. Treatment-induced changes in sCTX by clinical assay (Phase II only)

    Time frame: Baseline, cycle 1 day 1 pre-dose, cycle 1 day 8 pre-dose, cycle 1 day 15 pre-dose, day 1 of subsequent cycles (each cycle is 21 days), and end of treatment (estimated to be 10 months)

  3. Objective response rate (ORR) (Phase II only)

    Time frame: Through completion of treatment (estimated to be 10 months)

  4. Clinical benefit rate (Phase II only)

    Time frame: Through completion of treatment (estimated to be 10 months)

  5. Overall survival (OS) (Phase II only)

    Time frame: From start of treatment through completion of follow-up (estimated to be 3 years and 10 months)

  6. Treatment-induced changes in DEXA BMD (g/cm^2) at hip and spine (Phase II only)

    Time frame: Baseline, end of cycle 8, and end of treatment (estimated to be 10 months)

  7. Treatment-induced changes in quality of life as measured by EORTC QLQ-C30 (Phase II only)

    Time frame: Prior to start of 1st treatment, cycle 5 day 1, every 4 cycles thereafter (each cycle is 21 days), and at the time of progression (estimated to be 3 years and 10 months)

  8. Treatment-induced changes in pain as measured by Brief Pain Inventory (BPI) (Phase II only)

    Time frame: Prior to start of 1st treatment, cycle 5 day 1, every 4 cycles thereafter (each cycle is 21 days), and at the time of progression (estimated to be 3 years and 10 months)

  9. Number of participants with adverse events (Phase II only)

    Time frame: From start of treatment through 30 days after end of treatment (estimated to be 11 months)

07

Study locations

3 of 3 sites recruiting
  • The University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
    Recruiting
    • Qamar Khan, M.D. · Contact913-588-1227
    • Qamar Khan, M.D. · Principal investigator
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Ciara O'Sullivan, M.D., B.Ch. · Contact507-284-2511
    • Ciara O'Sullivan, M.D., B.Ch. · Principal investigator
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    Recruiting
    • Cynthia X Ma, M.D., Ph.D. · Contactcynthiaxma@wustl.edu · 314-362-8903
    • Cynthia X Ma, M.D., Ph.D. · Principal investigator
    • Sheila Stewart, Ph.D. · Sub investigator
    • Roberto Civitelli, M.D. · Sub investigator
    • Jingqin (Rosy) Luo, Ph.D. · Sub investigator
    • Foluso Ademuyiwa, M.D. · Sub investigator
    • Nusayba Bagegni, M.D. · Sub investigator
    • Ron Bose, M.D., Ph.D. · Sub investigator
    • Andrew Davis, M.D. · Sub investigator
    • Ashley Frith, M.D., Ph.D. · Sub investigator
    • Faisal Fa'ak, M.D. · Sub investigator
    • Lindsay Peterson, M.D. · Sub investigator
    • Rama Suresh, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — The investigator will share deidentified individual patient level data upon request after publication of the trial results.

Supporting information: Study protocol, Statistical analysis plan

Time frame: After publication of trial results.

Access criteria: Data use agreement will be needed and contact can be made with the Principal Investigator for requests.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for May 2032, 88 months after the start.

Of 167 non-industry phase 1/2 interventional studies under Breast Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 95. This study's planned 88 months is above that.

Counting every sponsor, half of 331 studies reached it within 62 months; a quarter within 45 and three quarters within 88.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2024
First posted
Apr 18, 2024
StartActual
Jan 30, 2025
Primary completionEst.
May 31, 2032
CompletionEst.
May 31, 2032
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Mayo Clinic is now Recruiting
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Mayo Clinic · Rochester, United StatesContact G•••@mayo.edu · •••2511→•••2511Contact person changed (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Mayo Clinic is now Recruiting
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Mayo Clinic · Rochester, United StatesContact G•••@mayo.edu · •••2511→•••2511Contact person changed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06374459
Collaborators
United States Department of Defense, Aclaris Therapeutics, Inc.
Responsible party
Sponsor
First posted
Apr 18, 2024
Start date
Jan 30, 2025
Primary completion
May 31, 2032 (estimated)
Completion
May 31, 2032 (estimated)
Last update
Oct 13, 2026

Study contacts

Cynthia X Ma, M.D., Ph.D.
Contact
cynthiaxma@wustl.edu
314-362-8903
Cynthia X Ma, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion